Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ColciGel is a prescription transdermal gel developed by Gensco Pharma for the treatment and prophylaxis of acute gout flares in adults. The active ingredient is Colchicinum 4X, a homeopathic preparation of colchicine, which acts by binding to tubulin and inhibiting microtubule polymerization. This mechanism reduces neutrophil-mediated inflammation at the site of application. The product utilizes Gensco's patented Isopeutic Transdermal Technology to deliver the medication directly through the skin to locally affected tissues, aiming to provide rapid relief (within 3-48 hours) while minimizing systemic absorption and the associated gastrointestinal side effects or drug interactions common with oral colchicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ColciGel.